However, "drug’s manufacturer will be required to conduct six postmarketing studies, including a long-term cardiovascular outcomes trial to assess the effect of Belviq on the risk for major adverse cardiac events such as heart attack and stroke" notes the FDA Press Release.
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.